Companies › Amgen · Global Markets & Policy
Amgen Inc.
- Nasdaq: AMGN
US biotechnology company making medicines for inflammation, cancer, bone, heart and rare diseases.
Amgen quarterly results and earnings history →
Insider trades (Form 4)
Last 120 days: open-market sales $4.1M, purchases $0. All Amgen insider transactions →
| Date | Insider | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Rachna Khosla SVP, Business Development | Open-market sale | 1,252 | $416.43 | $521K | Form 4 ↗ |
| Aug 11, 2026 | Rachna Khosla SVP, Business Development | Open-market sale | 2,000 | $412.57 | $825K | Form 4 ↗ |
| Aug 6, 2026 | Derek Miller SVP, Human Resources | Open-market sale | 2,069 | $402.54 | $833K | Form 4 ↗ |
| Aug 6, 2026 | Derek Miller SVP, Human Resources | Open-market sale | 1,821 | $402.54 | $733K | Form 4 ↗ |
| Aug 6, 2026 | Nancy A. Grygiel SVP & CCO | Open-market sale | 1,970 | $402.16 | $792K | Form 4 ↗ |
Key financials
| Metric | FY to Dec 2022 | FY to Dec 2023 | FY to Dec 2024 | FY to Dec 2025 |
|---|---|---|---|---|
| Revenue | $26.3B | $28.2B | $33.4B | $36.8B |
| Operating income | $9.6B | $7.9B | $7.3B | $9.1B |
| Net income | $6.6B | $6.7B | $4.1B | $7.7B |
| Diluted EPS | $12.11 | $12.49 | $7.56 | $14.23 |
Fiscal years, from annual reports (10-K / 20-F). Source: SEC EDGAR (XBRL company facts), retrieved 2026-10-14. Verify figures against the original filings.
Recent filings
- 2026-08-05 · 10-Q
- 2026-08-04 · 8-K — Results of operations
- 2026-07-31 · 8-K — Cybersecurity incident
- 2026-05-20 · 8-K — Shareholder vote results
- 2026-05-19 · 8-K — Director or officer change
- 2026-05-01 · 10-Q
- 2026-04-30 · 8-K — Results of operations
- 2026-04-22 · 8-K — Director or officer change
Source: SEC EDGAR, retrieved 2026-10-14. Filing types explained: 8-K, 10-Q, 10-K, 20-F / 6-K.
Not investment advice. This page lists official filings and our reports for reference. SignalStack does not rate securities or recommend buying or selling anything.